戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 h endogenous release and its use as a potent analgesic agent.
2 ohasubanonine was found to be an ineffective analgesic agent.
3 lar blocking agent (NMBA) without a sedative/analgesic agent.
4 erstanding of which may extend its use as an analgesic agent.
5 subject of great interest as potential novel analgesic agents.
6 rties, these compounds could be developed as analgesic agents.
7 tive cholinergic agonists will provide novel analgesic agents.
8 ll as blockade of the unwanted GI actions of analgesic agents.
9 be used as a template for the development of analgesic agents.
10 d antifungal agents), antiemetic agents, and analgesic agents.
11 hway may present a target for a new class of analgesic agents.
12 s, depth of sedation, and concomitant use of analgesic agents.
13 ffer strategies for the development of novel analgesic agents.
14 nzofurans (DHDMBFs) are antiinflammatory and analgesic agents.
15 ound to be nonsteroidal antiinflammatory and analgesic agents.
16 ostoperative pain relief compared with other analgesic agents.
17  potential nonsteroidal antiinflammatory and analgesic agents.
18  specific clinical applications for adjuvant analgesic agents.
19  opioid receptors have potential as improved analgesic agents.
20 ing safe and effective anti-inflammatory and analgesic agents.
21 bilized by methylene thioacetal as nonopioid analgesic agents.
22 her compounds are disclosed as novel, potent analgesic agents acting through neuronal nicotinic acety
23  It allows for gradual weaning from sedative/analgesic agents after prolonged sedation while eliminat
24 adrenergic agonists, a new class of sedative/analgesic agents and their possible application for cons
25       We also examine the development of new analgesic agents and treatment modalities and regimens f
26      Opiates and acetaminophen are preferred analgesic agents, and gabapentin is a contextual third c
27  a major health concern even though numerous analgesic agents are available.
28 holinergic effects but that it can act as an analgesic agent as well.
29 core and a decreased or stable use of rescue analgesic agents, as recorded in a daily electronic diar
30  selective CB2 agonism may afford a superior analgesic agent devoid of the centrally mediated CB1 eff
31 otent muscle relaxant, antiinflammatory, and analgesic agent (E)-2-(4,6-difluoro-1-indanylidene)aceta
32 mer and to the prototypical potent nicotinic analgesic agent (+/-)-epibatidine, 5 shows diminished ac
33        The use of gabapentin as an effective analgesic agent for neuropathic pain has expanded consid
34 al anti-inflammatory drugs versus other oral analgesic agents for acute soft tissue injury.
35                               Development of analgesic agents for the treatment of severe pain requir
36                         Clinically available analgesic agents generally lack efficacy and may have un
37 indicate that AM1710 is not a broad-spectrum analgesic agent in mice and suggest the need to identify
38 evidence that AK inhibitors may be useful as analgesic agents in a broad spectrum of pain states.
39 and NGF-neutralizing molecules are effective analgesic agents in many models of persistent pain.
40  and NGFneutralizing molecules are effective analgesic agents in many models of persistent pain.
41 review the evidence for the use of nonopioid analgesic agents in patients with cancer and describe th
42 cy, and withdrawal after the use of sedative/analgesic agents in the PICU population.
43 s after prolonged administration of sedative/analgesic agents include slowly tapering the intravenous
44         Clinical evaluation of 5f as a novel analgesic agent is currently underway.
45                    Morphine, a highly potent analgesic agent, is frequently prescribed for moderate t
46            Epidural analgesia, regardless of analgesic agent, location of catheter placement, and typ
47 ntinue use of alcohol and smoking and taking analgesic agents (nonsteroidal anti-inflammatory drugs a
48 sed the responsiveness of the measure to the analgesic agent remifentanil.
49                  The activation pattern with analgesic agents seems to be specific to the class of dr
50                                A 31-question analgesic agent survey was constructed, validated, and e
51         Because relief of pain is rewarding, analgesic agents that are not rewarding in the absence o
52  patient develops dental pain, we review the analgesic agents that are safe to take with warfarin and
53 e-based allosteric drug design of non-opioid analgesic agents that are specific to disease contexts.
54  therapeutics, including (i) fungistatic and analgesic agents that together generate fungicidal activ
55 elines allow physicians to give sedative and analgesic agents to dying patients if they intend to rel
56  promising therapeutic target for non-opioid analgesic agents to treat neuropathic pain(1,2).
57             Regular use of acetaminophen (an analgesic agent with little or no anti-inflammatory acti
58 ation of delirium and the use of sedative or analgesic agents with the outcomes were assessed with th
59 a-opioid agonists might represent more ideal analgesic agents, with fewer side effects.
60  Compound 2 is a potent antiinflammatory and analgesic agent without centrally acting muscle relaxant